title: [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates and premature infants. A study of cefozopran in the perinatal co-research group].
abstract: The following results were obtained in pharmacokinetic, bacteriological and clinical investigations of a cephem antibiotic for injection, cefozopran (SCE-2787, CZOP), administered to neonates and premature infants. 1. Pharmacokinetics (1) Half-lives (T 1/2's) of CZOP in 0-day-old (less than 24 hours after birth) neonates and premature infants were longer than those in 1-day-old or older infants. When half-lives were compared between 0-day-old neonates and 0-day-old premature infants, longer half-lives were observed in premature infants. (2) When CZOP was intravenously administered to 1-day-old or older neonates and premature infants at a dose of 20 mg/kg, no differences were noted in blood concentrations between neonates and premature infants from 30 minutes to 6 hours after administration as well as T 1/2's. (3) Blood concentration of CZOP administered at doses of 10, 20 and 40 mg/kg were dose-dependent. (4) Urine excretion rates of CZOP administered to 1-day-old or older neonates and premature infants were approximately 30 to 60% in the first 6 hours after administration. Urine excretion rates in 0-day-old neonates and premature infants were low. 2. Clinical results (1) Of a total of 136 cases to which CZOP was administered, clinical efficacy evaluation was possible in 96 cases, and safety evaluation in 132 cases. (2) The clinical efficacy rates were 78.6% (22/28) in 28 cases in which causative organisms were detected (Group A), and 97.1% (66/68) in 68 cases in which no such organisms were detected (Group B), with the total efficacy rate (Groups A and B) of as high as 91.7% (88/96). (3) Bacteriological evaluations were made with 33 strains isolated from the 28 cases of Group A. Elimination rates for Gram-positive and Gram-negative bacteria were 88.2% (15/17) and 92.3% (12/13), respectively, with the total elimination rate of 90.0% (27/30). No microbial substitution was noted. (4) As an adverse reaction, diarrhea was noted in one case (0.8%). Abnormal laboratory test values were noted in 15 cases (12.3%) including eosinophilia, elevated GPT, and elevated gamma-GTP. All of these abnormalities were transitory, and none of them critical. As a result of above pharmacokinetic and clinical investigations, CZOP is considered to be highly useful in the treatment of indicated infections in neonates and premature infants. It appears that 20 mg/kg of CZOP can be administered by intravenous injection or intravenous drip infusion to neonates and premature infants aged 0-day (less than 24 hours after birth) once or twice daily, to those aged 1 (24 or more hours after birth) to 7 days twice or three times daily, and to those aged 8 or more days three to four times daily, and that the dose can be increased up to 40 mg/kg in cases of critical or intractable infections.
authors.affiliation: Department of Pediatrics, School of Medicine, Teikyo University, (Research Institute of Chemotherapy for Mother and Child).
authors.forename: R
authors.initials: R
authors.lastname: Fujii
authors.forename: A
authors.initials: A
authors.lastname: Okuno
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.forename: F
authors.initials: F
authors.lastname: Kakuya
authors.forename: S
authors.initials: S
authors.lastname: Maruyama
authors.forename: H
authors.initials: H
authors.lastname: Sakata
authors.forename: F
authors.initials: F
authors.lastname: Inyaku
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: S
authors.initials: S
authors.lastname: Hashira
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazato
authors.forename: M
authors.initials: M
authors.lastname: Sugiura
authors.forename: T
authors.initials: T
authors.lastname: Tajima
authors.forename: S
authors.initials: S
authors.lastname: Nagai
authors.forename: N
authors.initials: N
authors.lastname: Funamoto
authors.forename: S
authors.initials: S
authors.lastname: Sugimori
authors.forename: S
authors.initials: S
authors.lastname: Nishimura
authors.forename: K
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Y
authors.initials: Y
authors.lastname: Kondoh
authors.forename: Y
authors.initials: Y
authors.lastname: Kawaoi
authors.forename: I
authors.initials: I
authors.lastname: Terashima
authors.forename: H
authors.initials: H
authors.lastname: Meguro
authors.forename: Y
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: M
authors.initials: M
authors.lastname: Kantake
authors.forename: K
authors.initials: K
authors.lastname: Sunakawa
authors.forename: M
authors.initials: M
authors.lastname: Yagisawa
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male; D000097586:Cefozopran
chemical_list: D002511:Cephalosporins; D000097586:Cefozopran